A novel study authored by a panel of federal appellate judges indicates that the United States Postal Service may be an unsafe vector for the distribution of reproductive medication. Medical experts caution that the legal findings remain preliminary and have not yet been peer-reviewed by the Supreme Court.
A recent ruling from the 5th U.S. Circuit Court of Appeals has introduced new clinical guidelines regarding the dispensing of mifepristone, a drug used in more than half of all abortions in the United States. While the Food and Drug Administration previously determined the medication was safe to send via mail, the appellate court’s latest data suggests that standard cardboard packaging and letter carriers could pose previously unstudied risks to patient health, requiring all doses to be handed over in person by a physician.
While the FDA has over two decades of pharmacological data, we must acknowledge that three appellate judges have introduced a compelling, albeit largely theoretical, hypothesis about the clinical dangers of the postal service.
Researchers at the American College of Obstetricians and Gynecologists stress that the court’s medical conclusions are highly irregular and rely on a relatively small sample size of zero clinical trials. Until further long-term epidemiological studies can be conducted on the precise medical dangers of priority shipping, experts advise patients to treat all federal judicial rulings regarding their personal health with an extreme degree of caution.